Sean Moloughney04.20.09
Galea Life Sciences, Aventura, FL, has received approval for Medicaid reimbursement in several key market states for its proprietary Nutraplete therapeutic drink mix.
Nutraplete is believed to be the first therapeutic nutritional dietary supplement created specifically to help people living with HIV/AIDS. This multi-nutritional, therapeutic functional food includes pharmaceutical grade supplements that may provide health benefits by addressing common nutritional deficiencies. Nutraplete is available by prescription and approved by many state Medicaid pharmacy programs.
Galea Life Sciences received approval for Medicaid reimbursement in New York, New Jersey, Connecticut, Nevada, Illinois and Washington state. The next group of states in which the company has applied for Medicaid reimbursement approval includes California, Texas, Florida, Pennsylvania and Maryland.
Once these additional Medicaid jurisdictions become Nutraplete-ready, the company will be able to market, with partner Allion Healthcare, to approximately 910,000 potential Nutraplete consumers, or approximately 70% of people living with HIV/AIDS in the U.S. In addition, there are 15 states where Nutraplete can immediately be prescribed and reimbursed by Medicaid with prior approval.
Paul Zuromski, chairman and president of Galea Life Science, said: "Our strategy is to make Nutraplete available through Medicaid pharmacy programs in areas of this country where it is most needed, and as soon as possible. This effort is being facilitated with our exclusive distributor, Allion Healthcare's MOMS Pharmacy, helping to make Nutraplete available to people living with HIV/AIDS in these Medicaid-approved states."
Nutraplete is believed to be the first therapeutic nutritional dietary supplement created specifically to help people living with HIV/AIDS. This multi-nutritional, therapeutic functional food includes pharmaceutical grade supplements that may provide health benefits by addressing common nutritional deficiencies. Nutraplete is available by prescription and approved by many state Medicaid pharmacy programs.
Galea Life Sciences received approval for Medicaid reimbursement in New York, New Jersey, Connecticut, Nevada, Illinois and Washington state. The next group of states in which the company has applied for Medicaid reimbursement approval includes California, Texas, Florida, Pennsylvania and Maryland.
Once these additional Medicaid jurisdictions become Nutraplete-ready, the company will be able to market, with partner Allion Healthcare, to approximately 910,000 potential Nutraplete consumers, or approximately 70% of people living with HIV/AIDS in the U.S. In addition, there are 15 states where Nutraplete can immediately be prescribed and reimbursed by Medicaid with prior approval.
Paul Zuromski, chairman and president of Galea Life Science, said: "Our strategy is to make Nutraplete available through Medicaid pharmacy programs in areas of this country where it is most needed, and as soon as possible. This effort is being facilitated with our exclusive distributor, Allion Healthcare's MOMS Pharmacy, helping to make Nutraplete available to people living with HIV/AIDS in these Medicaid-approved states."